Targeted alpha therapy for metastatic breast cancer using alpha-Herceptin [ 2003 - 2005 ]

Research Grant

Researchers: Prof Barry Allen (Principal investigator) ,  Prof John Kearsley

Brief description The specific aim of this proposal is to demonstrate, in non-human primates, proof–of-concept of a patented new platform vaccine technology (scrambled antigen vaccine or SAVINE) designed to encode all the protein sequences of an infectious agent, in this case HIV-1. These are arranged as equal-sized, overlapping fragments such that all potential T cell epitopes that are needed to induce broad T-cell-mediated immunity are maintained. The synthetically designed vaccine uses consensus sequences of HIV-1 to provide universal coverage of the major HIV-1 strains for a global population. The synthetic systematically designed HIV-1 vaccine will be delivered using our newly developed prime-boost immunisation regime that induces particularly high levels of cell-mediated immunity.

Funding Amount $AUD 332,420.00

Funding Scheme NHMRC Development Grants

Notes Development Grant